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A B S T R A C T
Within this work, we develop vesicles incorporating sub-unit antigens as solid dosage forms suitable for the oral
delivery of vaccines. Using a combination of trehalose, dextran and mannitol, freeze-dried oral disintegrating
tablets were formed which upon rehydration release bilayer vesicles incorporating antigen. Initial studies fo-
cused on the optimisation of the freeze-dry cycle and subsequently excipient content was optimised by testing
tablet hardness, disintegration time and moisture content. The use of 10% mannitol and 10% dextran produced
durable tablets which oﬀered strong resistance to mechanical damage yet appropriate disintegration times and
dispersed to release niosomes-entrapping antigen. From these studies, we have formulated a bilayer vesicle
vaccine delivery system as rapid disintegrating tablets and capsules.
1. Introduction
The oral route as a means of drug delivery and immunisation oﬀers
a range of advantages including ease of administration, reduced need
for trained personnel to administer vaccines and generally an increased
convenience and compliance. Furthermore, in the case of vaccines,
given that the mucosal sites are often the primary access point for
human pathogens, oral vaccination can enhance mucosal immunity and
promote strong resistance against many pathogens. In the development
of oral vaccines, a range of delivery systems have been considered in-
cluding liposomes and non-ionic surfactant vesicle carriers, such as
niosomes or bilosomes. These systems are employed to encapsulate/
associate vaccine antigens and thus provide protection and targeting
within the gastro-intestinal tract. In previous studies from our group,
we have shown that liposomes (Perrie et al., 2002) were able to protect
and deliver DNA vaccines orally and non-ionic vesicles (with and
without the addition of bile salts) were able to protect and deliver sub-
unit antigens to within the target site of the Peyer's Patches (Wilkhu
et al., 2013, 2014). Furthermore, these bilayer vaccines incorporating
recombinant HA were able to reduce median temperature diﬀerential
change and promote a reduction in viral cell load in an inﬂuenza
challenge study (Wilkhu et al., 2013).
In the development of an oral vaccine, generally the dosage form
has been in a liquid format. However in terms of shelf stability, storage
and distribution, vaccines in a liquid dosage form are not ideal and
development of a stable solid dosage vaccine platform is required. Solid
dosage forms such as tablets and capsules are the most commonly
adopted oral delivery system, oﬀering high patient compliance and easy
storage. In addition, options such as orally disintegrating tablets are
useful for paediatrics, geriatrics, patients who may struggle with
swallowing (after stroke or renal failure patients) or patients with
dysphasia (Lindgren and Janzon, 1991; Wilson et al., 1987; Gupta,
2010). Such solid dosage forms also oﬀer a cost eﬀective way to carry
out bulk immunisation, as tablets can be distributed worldwide without
the use of trained personnel.
To format liposomes into a dry format, freeze drying has been
widely used as a standard method. Freeze drying of liposomes is used to
prevent hydrolysis and physical degradation of the phospholipids
within the vesicles during extended storage (Van Winden, 2003;
Bridges and Taylor, 2001). However, the process of freezing and re-
sultant dehydration of the formulation can exert stress onto the vesicles
thus aﬀecting the integrity of the vesicles; freezing may result in ice
formation thus disrupting the bilayers and result in phase transition
changes (Stark et al., 2010). Furthermore, upon dehydration, an in-
crease in solute concentration can occur which may cause bilayer
fractures, subsequently leading to vesicle aggregation, changes in ve-
sicle size, and loss of entrapped antigen/material (Crowe et al., 1985;
Crowe et al., 1986; Stark et al., 2010).
The associated problems with freeze drying of bilayer vesicles can
be minimised by the inclusion of cryo- and lyoprotectants (which
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include disaccharide carbohydrate sugars) within the formulation prior
to freeze drying. Protectants such as trehalose or sucrose are char-
acterised by their non-eutectic nature, thus protecting the vesicles by
forming an amorphous matrix around the vesicles. The addition of
trehalose to a vesicle suspension inhibits vesicle fusion and aggregation
during the freezing process (Abdelwahed et al., 2006; Van Winden
et al., 1997). The mechanism of action of such cryoprotectants has been
examined by Crowe et al. (1996) where they found that the sugar
molecules are able to interact with the head groups of the phospholi-
pids, thus, preventing membrane disruption by counteracting fusion
(Crowe et al., 1996). In addition to using cryoprotectants to stablise the
suspensions, other excipients have also been known to aid in the lyo-
philisation process, oﬀering protection of the product. This includes
bulking agents such as hydroxyethyl starch, trehalose, mannitol, lac-
tose, and glycine. These are used when the concentration of product is
low. Stabilisers such as sucrose, lactose, trehalose and mannitol can be
used to oﬀer protection through the freezing stages and isotonicity
modiﬁers (e.g. mannitol, sucrose and glycerol) can be used to control
isotonicity. As can be seen, a range of studies have considered the
production of bilayer vesicles in a dried format; however, as noted by
Tan et al. (2013), to aid their clinical translation, research into con-
verting bilayer vesicles into convenient oral drug delivery systems is
required. Therefore, the aim of this work was to exploit such excipients
to formulate an oral vaccine solid dosage platform which, upon rehy-
dration or ingestion, releases the vesicles containing the antigen. These
vesicles should also maintain their integrity, potency and function as
they would in a liquid dosage form.
2. Materials and methods
To form the vesicles, the surfactants monopalmitoyl glycerol (MPG;
Larodan AG, Sweden), synthetic cholesterol (Chol), dicetyl phosphate
(DCP) (Sigma-Aldrich, UK) were used as this formulation has previously
been shown to act as a successful vaccine delivery system orally
(Wilkhu et al., 2013, 2014). The buﬀers were made up of sodium bi-
carbonate (Sigma-Aldrich, UK) at pH 7.6, where hydrochloric acid and
sodium hydroxide (NaOH) (Sigma-Aldrich, UK) were used for pH ad-
justments. For the antigen, a recombinant H3N2 sub-unit protein (Im-
mune Tech, USA) was used.
2.1. Preparation of vesicles for lyophilisation
A 5:4:1 M ratio of MPG, CHO and DCP was weighed and placed into
a 10 mL glass beaker. 25 mM sodium bicarbonate (pH 7.6) formed the
aqueous phase and was placed in a heated water bath for 10 min at
30–35 °C. Whilst the aqueous buﬀer was preheated, the beaker con-
taining the lipids was placed into a hot oil bath (120–125 °C) and
melted for 10 min with occasional mixing. The beaker containing the
molten mixture was removed from the oil bath and the buﬀered stock
solution was immediately added and homogenised at 8000 rpm at
30–35 °C. After homogenising for 10 min, the homogenisation speed
was reduced to 4000 rpm to act as a mixer and dextran (Sigma Aldrich,
UK) was added into the solution for a minute followed by mannitol
(Sigma Aldrich, UK) for another minute of mixing. A 400 mM trehalose
solution was prepared and then added at a 1:1 ratio of vesicle mixture:
trehalose in a bijoux tube which formed the mould for the tablets and
were then pre-frozen in the−70 °C freezer until the freeze drying cycle
was ready to begin.
3. Lyophilisation cycle
Lyophilisation was performed with the Virtis Advantage (Bio
Pharma) freeze dryer. The freeze drying protocol was set for primary
drying to occur at−40 °C for 48 h with a secondary drying cycle set at
Dried lipid product
Frozen sample
D) Temperature (° C) Time (h)
Pre - freezing -70 1
Primary drying -40 48
Secondary drying +20 10
A) B) 
C) 
Fig. 1. Samples undergoing lyophilisation where: A) Samples are in process during a freeze drying cycle. B) Sublimation taking place within a vial containing the vesicle formulation.
Temperature probes are constantly monitoring internal temperature over the time period of the lyophilisation cycle. C) Key stages during a freeze drying cycle taken using a thermocouple
placed inside vesicle suspension vials with and without sucrose. D) Final optimised parameters for lyophilisation of vesicles with condenser temperature set at −75 °C.
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B) After lyophilisation
Vesicle size (µm) 5.85 ± 0.31
Zeta potential (mV) -66.8 ± 9.7
A) Pre lyophilisation
Vesicle size (µm) 6.12 ± 0.09
Zeta potential (mV) -64.5 ± 6.9
Fig. 2. Vesicle characterisation data for vesicles prior to and after
lyophilisation and imaged using freeze-fracture on Balzers appa-
ratus at −110 °C where images were then taken on a Jenway
transmission electron microscope where: A) represents vesicles prior
to freeze drying and B) rehydrated vesicles after freeze drying. Line
bar represents 0.5 and 1 μm (A) and 2 and 1 μm (B).
Trehalose Sucrose
Vesicle Size
(µm)
Zeta potential 
(mV)
Vesicle Size
(µm)
Zeta potential 
(mV)
Pre freeze drying 5.88 ± 0.05 -68.54  ± 6.4 5.88 ± 0.05 -68.54  ± 6.4
Lyophilised tablets
Reconstituted vesicles 6.55 ± 0.12 -59.8  ± 8.9 8.42 ± 0.45 -54.8  ± 12.1
Fig. 3. Final lyophilised tablets of vesicles containing 5% w/w mannitol representing appearance and handling protected with 200 mM ﬁnal concentration of either A) trehalose and B)
sucrose (n= 5).
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20 °C for a further 10 h with a condenser temperature set at −75 °C.
3.1. Freeze fracture microscopy of vesicles
A 5 μL drop of each incubation mixture was placed on a ridged, gold
specimen support or was sandwiched between two copper plates for
fracture in a double replica device. Samples were frozen by rapid
plunging into a constantly stirred mixture of propane:isopentane (3:1)
cooled by liquid nitrogen. Fracture was performed on a Balzers BAF
400D apparatus at a temperature of −110 °C. Replicas were ﬂoated
free on distilled water and cleaned in 40% chromic acid. Images were
then viewed using a Jenway transmission electron microscope.
3.2. TGA of freeze dried tablets
A small sample of the tablets were broken and the sample was
placed onto the Perkin Elmer TGA apparatus, weighed and then ana-
lysed. The sample was heated to 110 °C and moisture content was de-
termined as a % weight loss of the sample. All samples were repeated in
triplicate to determine moisture content and degradation. All for-
mulations were carried out using nitrogen and air as the purge gasses.
3.3. Mechanical strength
The mechanical properties (Hardness) of the tablets were analysed
by a Tinius Olsen texture analyser (Hounsﬁeld, UK) equipped with a
50 N load cell. The instrument was calibrated with standard weights
and the tablets were placed individually on a platform. The hardness
was expressed as the peak force (N) after a 2 mm penetration of a 5 mm
diameter probe at velocity of 6 mm/min was applied. The average of
ﬁve batches was taken as replicates.
3.4. Disintegration time
Disintegration time was measured using the USP apparatus
(Erweka, ZT3) test for disintegration where 800 mL distilled water was
kept at constant temperature of 37 °C. A basket with a wire mesh was
raised up and down within this 800 mL media at an interval of 30 cy-
cles/min. Samples were run individually and were tested in triplicate.
3.5. Determination of vesicle size and zeta potential
The vesicle size distribution was determined using laser diﬀraction
on a sympatec 2005 (Helos/BF) cuvette analyser. 20 μL of the vesicle
suspension was diluted into the cuvette with 40 mL double distilled
water. The zeta potential was measured in 1.5 mL double distilled water
at 25 °C on a Zeta Plus Brookhaven Instrument.
3.6. Labelling and quantiﬁcation of Antigen
Initially the H3N2 antigen was incubated with the ﬂuorescent
ﬂamma ﬂuor FPR-648 (Bio Acts) marker and a conjugation buﬀer was
added and left at 30 °C for 4 h to conjugate. After this period the un-
bound ﬂuorescence was removed by centrifugation through an amicon
P-10 centrifugal 10 kD MWCO ﬁlter tube. The remaining ﬂuorescent
antigen was made back to volume and then a spike of this was used per
formulation. The H3N2 spike was placed into the aqueous phase prior
to homogenisation. Initially a calibration curve was constructed on the
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Fig. 4. The result of varying mannitol and dextran ratios within the vesicle mixture where; A) outlines the vesicle characteristics, B) presents the appearance of the tablets, their hardness
and disintegration time and C) their moisture content (n= 5).
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same plate as the formulations and all conditions for all formulations
was kept constant. Vesicles were prepared incorporating the ﬂuorescent
antigen and freeze dried. For quantiﬁcation of antigen association,
ultra-centrifugation of the formulations was required to isolate antigen
entrapped vesicles, from non-incorporated antigen. To achieve this,
freeze dried samples were rehydrated and 300 μL aliquots of sample
were diluted in a Beckman 3.9 mL Polo-allomer tube and centrifuged at
354,000×g for 45 min at 4 °C. This was repeated and the antigen
loaded vesicles were then re-suspended with 100–200 μL of appropriate
buﬀer and transferred to a black microplate for reading ﬂuorescence
and antigen quantiﬁcation.
3.7. Statistical analysis
The results within this study are given as the mean ± S.D. unless
stated otherwise. Diﬀerences between results were analysed by ANOVA.
A probability factor of< 0.05 (p < 0.05) was considered to represent
statistically signiﬁcant diﬀerence.
4. Results and discussion
4.1. Optimisation of Freeze drying cycle
Lyophilisation is a time-consuming and energy intensive process,
thus optimisation of a cycle is vital (Hilleman and Hurni, 1982). The
ﬁrst step of freeze drying is the thermal treatment of the formulation
i.e., pre-freezing, where the liquid suspension is cooled and ice crystals
are formed. As previously mentioned, the presence of ice crystals may
disrupt bilayers and lead to vesicle instability (Stark et al., 2010). In
general, fast freezing results in smaller ice crystals being produced,
compared to slow freezing which results in large crystals and pores. As
a result, pre freezing of the liquid suspensions can be carried out by
freezing at −70 °C to overcome the issue of producing large crystals
and larger pores.
Initially, the lyophilisation procedure for lipid based vesicles within
this study was obtained from the development of a freeze drying pro-
tocol for TB-liposomal vaccines (Mohammed et al., 2006; Mohammed
et al., 2007). Within these studies, it was found that liposomes, with the
inclusion of a cryoprotectant, when pre frozen at −70 °C followed by
10 h primary drying at −50 °C with 24 h secondary drying at −30 °C
was a suitable protocol, as shown by the vesicle size after rehydration
(Mohammed et al., 2006). The preparation of vesicles in this present
study includes the use of signiﬁcantly higher lipid concentrations
within the formulations compared to the previous studies (Mohammed
et al., 2006), hence the lyophilisation cycle was further optimised for
drying times. This was carried out as presented in Fig. 1 where ther-
mocouples were added to vials containing vesicles (Fig. 1 A and B) and
Fig. 1B shows the sublimation front moving down through the sample.
Fig. 1C presents this data where the shelf temperature was kept con-
stant at −40 °C and the change in temperature based on the thermo-
couples recorded the temperatures with and without a cryoprotectant.
Fig. 1C shows that there was no deviation in temperature change be-
tween 30 and 75 h of primary drying, implying that the temperature
within the lipid cake is constant thus a primary drying time between
this time point can be adopted. Fig. 1C also demonstrates that the ad-
dition of a cryoprotectant (200 mM sucrose) allows primary drying to
take place at a higher temperature (−20 °C) as presented by the yellow
line in the ﬁgure.
Based on these results in Fig. 1, the ﬁnal optimised protocol for the
vesicles used primary drying for 48 h with a shelf temperature of
−40 °C. Size and zeta potential measurements, and freeze fracture
images (Fig. 2) conﬁrm the presence of bilayer vesicles prior to and
after freeze drying, where Fig. 2A represents vesicles prior to freeze
drying and Fig. 2B representing rehydrated vesicles after freeze drying.
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B) Formulation antigen loading Antigen entrapment (%)
Liquid vesicles 39 ± 2.5
Freeze- driedvesicles within capsules 30 ± 3.8
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Fig. 5. Vesicles containing antigen formatted as liquids, a freeze-dried tablet and ODTs where A) shows the various formulations B) shows antigen incorporation, C), outlines the vesicle
characteristics and D) the disintegration time (n= 5).
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These results demonstrate that the size and zeta potential of the vesicles
remaining unchanged after freeze-drying and re-suspension. Further
chemical analysis was not undertaken of these formulations given the
noisome components used within this study are widely recognised as
stable and key attributes of concern for this work were the vesicle
characteristics.
4.2. Formatting vesicles in oral dispersible tablets
To develop a freeze-dried tablet formulation of vesicles, mannitol
was adopted as an additive as it is known to add bulking and stabili-
sation properties to the ﬁnal freeze dried product (Seager, 1998).
Mannitol is also water soluble and non-hygroscopic which provides a
cooling sensation when in the mouth (Jeong et al., 2008). In addition,
sucrose was compared with trehalose to determine any eﬀects of pro-
tectant on the ﬁnal product characteristics.
Fig. 3 demonstrates the properties of the vesicles before freeze-
drying and after reconstitution of the freeze-dried tablets containing
200 mM ﬁnal concentration of either trehalose or sucrose. With the
addition of sucrose as the cryoprotectant, a signiﬁcant (p < 0.05) in-
crease in vesicle size after rehydration was noted, with vesicles in-
creasing to 8.42 ± 0.45 μm, compared to trehalose formulations
where the vesicle size was retained (Fig. 3). In both cases, the anionic
nature of the vesicles was retained (Fig. 3). Redispersion of the samples
was carried out with 2 mL water and resuspension time was< 5 s
(results not shown). The dispersion time of the tablets was rapid due to
the matrix being prepared from water soluble sugars (sucrose/treha-
lose) thus allowing the moulded tablets to rapidly disintegrate. How-
ever, these moulded tablets had poor mechanical strength as demon-
strated in Fig. 3; on removal of the tablets from the moulds, the
handling was compromised. The highly porous nature of the freeze
dried tablets results in their fragile properties. In general, freeze dried
tablets such as Claritin® RediTabs® have highly porous inner structures
which results in immediate disintegration and dissolving of the tablets
upon the tongue (Fu et al., 2004). To increase the handling of the ta-
blets, either direct compression can be used and/or binding agents can
be added to the formulation. Therefore to improve the structural in-
tegrity and handling ability of the tablets in Fig. 3, the addition of
diﬀerent combinations of dextran and mannitol prior to lyophilisation
was investigated (Fig. 4). The inclusion of a strawberry ﬂavouring to
one of the formulations was also considered. The formulations were
tested for tablet hardness, disintegration time and resuspended to
conﬁrm vesicle size and zeta potential.
Prior to addition of excipients the vesicles were around 6 μm with a
zeta potential of −60 to −70 mV (results not shown) in line with the
results in Fig. 3. Upon addition of excipients, the vesicle size range
decreases, which could be due to the dextran pulling down the volume
mean diameter, and after lyophilisation and rehydration all of the
formulations were approximately 4.5 μm (Fig. 4). The zeta potential
values upon rehydration showed no signiﬁcant diﬀerences between
them and were around −45 to −55 mV and less negative than the
initial readings prior to excipient addition (Fig. 4). Dextran and man-
nitol, are key excipients in controlling mechanical hardness and disin-
tegration time (Chandrasekhar et al., 2009; Seager, 1998). Fig. 4B de-
monstrates that tablets containing 5% w/w dextran and 10% w/w
mannitol have a tablet strength of 4 to 6 N and a disintegration time of
approximately 10 s (Fig. 4) and increasing the mannitol content to 15%
made no signiﬁcant diﬀerence (p < 0.05). However, when the dextran
content was increased to 10% both the tablet hardness and disin-
tegration time increases and again, the diﬀerence in mannitol content
(10 or 15%) made no signiﬁcant diﬀerence. The addition of 1% v/v
strawberry ﬂavour to the formulation showed signiﬁcantly (p < 0.05)
higher tablet hardness (16 ± 1.4 N) and the tablets were prone to
fracturing, resulting in the longest disintegration time. Studies have
shown that the matrix of freeze dried tablets that consist of polymers
such as gelatins, dextrans or alginates provide structural strength and
saccharides such as mannitol or sorbitol provide crystallinity, hardness
and elegance (Sastry et al., 2000). In the case of the freeze-dried vesicle
formulations, all tablets produced are within the rapid disintegrating
tablets class based on FDA criteria (where rapid disintegrating tablets
should disintegrate in< 30 s (Mclaughlin et al., 2009, FDA, 2008)).
To determine moisture content within the formulations, thermo-
gravimetric analysis studies (Fig. 4C) was carried based on a similar
protocol to Mohammed et al. (2006) and all formulations were below
the 5% moisture content threshold. The importance of moisture content
within lyophilised tablets is due to the sensitivity of the excipients to
residual moisture, which can impair long term stability and disin-
tegration times. Furthermore, traces of moisture in a tablet may lead to
longer term stability issues such as, friability, dissolution, microbial
contamination and issues in the stability of the vesicles within the
freeze-dried tablet. The moisture content results within this study are in
line with Mohammed et al., (2006) where it was shown that cationic
liposome vesicles, with the use of trehalose as the cryoprotectant, after
freeze drying had residual moisture content levels< 5% (Mohammed
et al., 2006). When correlating moisture content with tablet hardness,
the results show that dextran content of 5% w/v results in higher
moisture content (~4%) within the tablets and also reduced tablet
hardness (4–6 N; Fig. 4). Water can aﬀect the physical properties of
freeze dried solids by inducing cake softening, cake collapse, crystal-
lisation of amorphous solids, polymorphic conversions between crys-
talline structures and protein aggregation by increasing mobility within
the solid (Costantino and Pikal, 2004). Studies by Nakabayashi et al.,
(1980) also demonstrated that the increase in moisture content within
the lactose- corn starch tablets rapidly decreased the hardness of the
tablets (Nakabayashi et al., 1980). Studies by Sugimoto et al. (2006)
demonstrate that mannitol absorbed little moisture upon increase in
relative humidity compared to excipients such as glucose or sorbitol
(Sugimoto et al., 2006).
4.3. Formulation of vesicles entrapping antigen within solid dosage forms
The results in Fig. 4 show that the tablets incorporating freeze-dried
vesicles can be formatted as rapid disintegrating tablets. However, the
tablets produced still expose the vesicles to the external milieu of the
stomach which can result in vesicle breakdown and/or loss of en-
trapped antigen if designed for the delivery of vaccines. Hence, as an
alternative to tabletting, freeze dried vaccine formulations within
capsules were also examined. Therefore vesicles were prepare con-
taining the H3N2 antigen and loaded within capsule shells and compare
the rehydration characteristics to a control tablet to ensure the capsule
is not interfering with the vesicles.
The capsule formulations did not require the use of additives such as
dextran or mannitol as the capsule shell provides structural integrity
thus increasing handling and protection of the vesicular vaccines en-
closed. The capsule shells are presented in Fig. 5A with a ﬁll volume of
0.5 mL. Antigen loading, vesicle size distribution and surface charge
was analysed prior to and after the freeze drying (Fig. 5). The initial
vesicle size is comparable to previous formulations with an average
vesicle size of 6–6.5 μm and a highly negative zeta potential (≥65 mV).
After freeze-drying within the capsules, the contents were rehydrated
with 0.5 mL ultrapure water, vortexed and then analysed for vesicle size
and charge. The vesicles from the capsules reduced in size to an average
of 4 to 5 μm with the zeta potential remaining highly negative (Fig. 5)
which is within the size range suitable for uptake by the Peyer's patches
(Tabata and Ikada, 1988; Ebel, 1990; Eldridge et al., 1990; Tabata et al.,
1996).
Similarly, antigen loading within the vesicles was compared across
all 3 dosage form platforms (liquid, freeze-dried capsules and ODT).
Antigen loading was 30 to 40% of initial amount used, in line with the
antigen loading of vesicles prior to freeze-drying (Fig. 5B). Fig. 5D re-
presents the disintegration time of the capsule and the control tablet
formulation within gastric media (pH 1.2). Results show that the tablets
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disintegrate within 5 s, compared to the capsules which have a disin-
tegration/ release time of 5–6 min. In both cases, complete dispersion
of the freeze-dried product and release of the niosomes was achieved.
Capsules prepared by Jones et al. (2012), have shown that in humans in
the fasted state, gelatin based capsules disintegrate within 7 ± 3 min
compared to a fed state of 12 ± 3 min (Jones et al., 2012). The cap-
sules prepared within this study oﬀer this delayed release proﬁle of
6 min and reduces the contact time of the vesicles and potentially any
drugs/antigens prone to acid or enzymatic degradation within the
stomach.
5. Conclusion
Within this study, we have produced an alternative solid dosage
forms for the oral delivery of bilayer vesicles. Such systems can provide
a more convenient and cost-eﬀective delivery system for oral vaccine
systems by helping the distribution and access to patients. Should im-
proved targeting to the intestine be required, delayed release capsules
could also be adopted to ensure the bilayer vesicle systems are not re-
leased until the small intestine. Furthermore, depending on the lipid
composition and antigen selected, additional studies to assure the va-
lidity of the antigen may be required. However with the current bilayer
vesicles, previous studies have shown these vesicles are stable within
the GI tract, are taken up by the M cells and stimulate an immune re-
sponse (Wilkhu et al., 2013), therefore the primary outcome of this
study was to format the formulation in an easy to use solid dosage form.
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